[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-330462-105":59,"doc-detail-330462-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","development-of-a-serum-based-microrna-signature-for-early-detection-of-pancreatic-cancer-a-multicenter-cohort-study","Development of a Serum-Based MicroRNA Signature for Early Detection of Pancreatic Cancer - A Multicenter Cohort Study","","Pancreatic cancer has a grim prognosis largely because early diagnosis remains difficult, making improved biomarkers urgently needed to raise patient survival. This multicenter cohort study first identified candidate microRNAs using microarray profiling of formalin-fixed, paraffin-embedded tissues, then validated clinical utility in serum specimens. Retrospective recruitment covered 1,273 participants across four centers, analyzed via real-time PCR. A four-miRNA panel achieved strong discrimination for early-stage disease versus controls and related pancreatic conditions, showing high diagnostic AUCs.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-of-a-serum-based-microrna-signature-for-early-detection-of-pancreatic-cancer-a-multicenter-cohort-study/330462/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-of-a-serum-based-microrna-signature-for-early-detection-of-pancreatic-cancer-a-multicenter-cohort-study/330462.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-14","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is early detection of pancreatic cancer difficult and important?","Question",{"text":112,"@type":113},"The disease has extremely poor outcomes, and low survival is driven by challenges in diagnosing it early. More than two-thirds of patients are diagnosed at regional or distant metastatic stages due to a lack of typical symptoms.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were candidate microRNAs identified and validated in this study?",{"text":117,"@type":113},"Candidate microRNAs were identified in FFPE tissues using microarray profiles, then validated using a serum-based cohort. Serum specimens were analyzed using real-time polymerase chain reaction.",{"name":119,"@type":110,"acceptedAnswer":120},"What diagnostic performance did the four-serum-miRNA panel achieve?",{"text":121,"@type":113},"The panel discriminated early-stage pancreatic cancer from healthy controls and non-PCa conditions, outperforming common markers including CA19-9, CA125, CEA, and CA242. It reported AUC values of 0.971 and 0.924 in the respective comparisons and showed specificity of 90.2%.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},330462,1790671030,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Digestive Diseases and Sciences (2024) 69:1263–1273  \n[https://doi.org/10.1007/s10620-024-08338-4](https://doi.org/10.1007/s10620-024-08338-4)  \nDevelopment of a Serum‑Based MicroRNA Signature for Early Detection of Pancreatic Cancer: A Multicenter Cohort Study  \nJing Huang1 · Ge Gao2 · Yang Ge4 · Jianzhou Liu3 · Hongtu Cui5 · Ren Zheng1 · Jialin Wang1 · Si Wang1 ·  \nVay Liang Go6 · Shen Hu6 · Yefu Liu7 · Minwei Yang8 · Yongwei Sun8 · Dong Shang9 · Yantao Tian10 · Zhigang Zhang11 · Zhongyuan Xiang2 · Hongyang Wang12 · Junchao Guo3 · Gary Guishan Xiao1,6,13  \nReceived: 29 November 2023 / Accepted: 5 February 2024 / Published online: 7 March 2024 © The Author(s) 2024  \nAbstract  \nBackground A grim prognosis of pancreatic cancer (PCa) was attributed to the difficulty in early diagnosis of the disease. Aims Identifying novel biomarkers for early detection of PCa is thus urgent to improve the overall survival rates of patients. Methods The study was performed firstly by identification of candidate microRNAs (miRNAs) in formalin-fixed, paraffinembedded tissues using microarray profiles, and followed by validation in a serum-based cohort study to assess clinical utility of the candidates. In the cohorts, a total of 1273 participants from four centers were retrospectively recruited as two cohorts including training and validation cohort. The collected serum specimens were analyzed by real-time polymerase chain reaction.  \nResults We identified 27 miRNAs expressed differentially in PCa tissues as compared to the benign. Of which, the top-four was selected as a panel whose diagnostic efficacy was fully assessed in the serum specimens. The panel exhibited superior to CA19-9, CA125, CEA and CA242 in discriminating patients with early stage PCa from healthy controls or non-PCa including chronic pancreatitis as well as pancreatic cystic neoplasms, with the area under the curves (AUC) of 0.971 (95% CI 0.956–0.987) and 0.924 (95% CI 0.899–0.949), respectively. Moreover, the panel eliminated interference from other digestive tumors with a specificity of 90.2% .  \nConclusions A panel of four serum miRNAs was developed showing remarkably discriminative ability of early stage PCa from either healthy controls or other pancreatic diseases, suggesting it may be developed as a novel, noninvasive approach for early screening of PCa in clinic.  \nGraphical Abstract  \nKeywords Pancreatic cancer · Serum · Circulating microRNA · Diagnosis · Noninvasive biomarker  \nExtended author information available on the last page of the article  \nIntroduction  \nPancreatic adenocarcinoma is the fourth leading cause of cancer-related mortality, and it is projected to become the second leading cause of cancer death by 2030 [1] . Pancreatic cancer (PCa) is characterized by extremely poor outcomes, with the 5-year relative survival rate of approximately 10%[2] . This low cancer survival rate is attributable to the difficulty in early diagnosis. Because of the lack of typical symptoms, more than two-thirds of patients with PCa are diagnosed with either regional or distant metastasis [3]. Early detection is a critical strategy for improving the overall survival of patients with PCa.  \nUnfortunately, current clinical diagnostic approaches for PCa are ineffective owing to their low sensitivity and/ or specificity. Clinical diagnostic methods include imaging techniques and blood-based biomarkers . Imaging modalities, such as multidetector computed tomography, magnetic resonance imaging, and endoscopic ultrasonography with fine-needle aspiration, were limited by their disadvantages [4] . Carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 242 (CA242), carbohydrate antigen 125 (CA125), and carcinoembryonic antigen (CEA) are the common blood-based biomarkers for the clinical diagnosis of PCa [5] . However, the accuracy of these biomarkers is not strong because of their non-specific aberration in cancers other than PCa [6] . Though CA19-9 is the bestvalidated biomarker with a ","cbCairUoe9ImItNG","https://ap.wps.com/l/cbCairUoe9ImItNG","pdf",3833058,11,"English","# Abstract\n## Background\n## Aims\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Materials and Methods\n## Study Design and Participants","[{\"question\":\"Why is early detection of pancreatic cancer difficult and important?\",\"answer\":\"The disease has extremely poor outcomes, and low survival is driven by challenges in diagnosing it early. More than two-thirds of patients are diagnosed at regional or distant metastatic stages due to a lack of typical symptoms.\"},{\"question\":\"How were candidate microRNAs identified and validated in this study?\",\"answer\":\"Candidate microRNAs were identified in FFPE tissues using microarray profiles, then validated using a serum-based cohort. Serum specimens were analyzed using real-time polymerase chain reaction.\"},{\"question\":\"What diagnostic performance did the four-serum-miRNA panel achieve?\",\"answer\":\"The panel discriminated early-stage pancreatic cancer from healthy controls and non-PCa conditions, outperforming common markers including CA19-9, CA125, CEA, and CA242. It reported AUC values of 0.971 and 0.924 in the respective comparisons and showed specificity of 90.2%.\"}]","Development of a Serum-Based MicroRNA Signature for Early Detection of Pancreatic Cancer - A Multicenter Cohort Study | PDF",1789989040,28]